Literature DB >> 28435157

The systemic nature of CKD.

Carmine Zoccali1, Raymond Vanholder2, Ziad A Massy3,4,5,6,7, Alberto Ortiz8, Pantelis Sarafidis9, Friedo W Dekker10, Danilo Fliser11, Denis Fouque12, Gunnar H Heine11, Kitty J Jager13, Mehmet Kanbay14, Francesca Mallamaci1,15, Gianfranco Parati16, Patrick Rossignol7,17,18,19,20, Andrzej Wiecek21, Gerard London22.   

Abstract

The accurate definition and staging of chronic kidney disease (CKD) is one of the major achievements of modern nephrology. Intensive research is now being undertaken to unravel the risk factors and pathophysiologic underpinnings of this disease. In particular, the relationships between the kidney and other organs have been comprehensively investigated in experimental and clinical studies in the last two decades. Owing to technological and analytical limitations, these links have been studied with a reductionist approach focusing on two organs at a time, such as the heart and the kidney or the bone and the kidney. Here, we discuss studies that highlight the complex and systemic nature of CKD. Energy balance, innate immunity and neuroendocrine signalling are highly integrated biological phenomena. The diseased kidney disrupts such integration and generates a high-risk phenotype with a clinical profile encompassing inflammation, protein-energy wasting, altered function of the autonomic and central nervous systems and cardiopulmonary, vascular and bone diseases. A systems biology approach to CKD using omics techniques will hopefully enable in-depth study of the pathophysiology of this systemic disease, and has the potential to unravel critical pathways that can be targeted for CKD prevention and therapy.

Entities:  

Mesh:

Year:  2017        PMID: 28435157     DOI: 10.1038/nrneph.2017.52

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  270 in total

1.  Heritability of measures of kidney disease among Zuni Indians: the Zuni Kidney Project.

Authors:  Jean W MacCluer; Marina Scavini; Vallabh O Shah; Shelley A Cole; Sandra L Laston; V Saroja Voruganti; Susan S Paine; Alfred J Eaton; Anthony G Comuzzie; Francesca Tentori; Dorothy R Pathak; Arlene Bobelu; Jeanette Bobelu; Donica Ghahate; Mildred Waikaniwa; Philip G Zager
Journal:  Am J Kidney Dis       Date:  2010-06-19       Impact factor: 8.860

Review 2.  Nonthyroidal illness and the cardiorenal syndrome.

Authors:  Christiaan L Meuwese; Olaf M Dekkers; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2013-09-03       Impact factor: 28.314

Review 3.  Systemic consequences of poor oral health in chronic kidney disease patients.

Authors:  Harun Akar; Gulcan Coskun Akar; Juan Jesús Carrero; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 8.237

4.  High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease.

Authors:  Davide Bolignano; Simone Lennartz; Daniela Leonardis; Graziella D'Arrigo; Rocco Tripepi; Insa E Emrich; Francesca Mallamaci; Danilo Fliser; Gunnar Heine; Carmine Zoccali
Journal:  Kidney Int       Date:  2015-02-18       Impact factor: 10.612

5.  Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.

Authors:  Ann V Schwartz; Anne L Schafer; Andrew Grey; Eric Vittinghoff; Lisa Palermo; Li-Yung L Lui; Robert B Wallace; Steven R Cummings; Dennis M Black; Douglas C Bauer; Ian R Reid
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

6.  Mineral metabolites and CKD progression in African Americans.

Authors:  Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

7.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle.

Authors:  Stefan Engeli; Andreas L Birkenfeld; Pierre-Marie Badin; Virginie Bourlier; Katie Louche; Nathalie Viguerie; Claire Thalamas; Emilie Montastier; Dominique Larrouy; Isabelle Harant; Isabelle de Glisezinski; Stefanie Lieske; Julia Reinke; Bibiana Beckmann; Dominique Langin; Jens Jordan; Cedric Moro
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

8.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

9.  Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.

Authors:  Chiao-Yin Sun; Shih-Chung Chang; Mai-Szu Wu
Journal:  Kidney Int       Date:  2012-01-11       Impact factor: 10.612

10.  A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

Authors:  Sahir Kalim; Clary B Clish; Julia Wenger; Sammy Elmariah; Robert W Yeh; Joseph J Deferio; Kerry Pierce; Amy Deik; Robert E Gerszten; Ravi Thadhani; Eugene P Rhee
Journal:  J Am Heart Assoc       Date:  2013-12-05       Impact factor: 5.501

View more
  88 in total

Review 1.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Aiqing Li
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

2.  Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.

Authors:  Rabi Yacoub; Girish N Nadkarni; Daniel I McSkimming; Lee D Chaves; Sham Abyad; Mark A Bryniarski; Amanda M Honan; Shruthi A Thomas; Madan Gowda; John C He; Jaime Uribarri
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

Review 3.  The Interconnection Between Immuno-Metabolism, Diabetes, and CKD.

Authors:  Fabrizia Bonacina; Andrea Baragetti; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Curr Diab Rep       Date:  2019-03-19       Impact factor: 4.810

4.  Nephrology a discipline evolving into complexity: between complex systems and philosophy.

Authors:  Natale G De Santo
Journal:  J Nephrol       Date:  2019-11-27       Impact factor: 3.902

5.  Association between albumin-to-globulin ratio and long-term mortality in patients with chronic kidney disease: a cohort study.

Authors:  Mengru Zeng; Yu Liu; Fuyou Liu; Youming Peng; Lin Sun; Li Xiao
Journal:  Int Urol Nephrol       Date:  2020-05-13       Impact factor: 2.370

Review 6.  Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes.

Authors:  Christian Herder; Norbert Hermanns
Journal:  Semin Immunopathol       Date:  2019-02-18       Impact factor: 9.623

Review 7.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 8.  WNT-β-catenin signalling - a versatile player in kidney injury and repair.

Authors:  Stefan J Schunk; Jürgen Floege; Danilo Fliser; Thimoteus Speer
Journal:  Nat Rev Nephrol       Date:  2020-09-28       Impact factor: 28.314

Review 9.  Mitochondrial dysfunction in diabetic kidney disease.

Authors:  Josephine M Forbes; David R Thorburn
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

Review 10.  The impact of exercise on physical function, cardiovascular outcomes and quality of life in chronic kidney disease patients: a systematic review.

Authors:  Baris Afsar; Dimitrie Siriopol; Gamze Aslan; Ozgur C Eren; Tuncay Dagel; Ugur Kilic; Asiye Kanbay; Alexandru Burlacu; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-01-17       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.